Description: ResMed Inc. is a holding company. The Company is engaged in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders, including sleep disordered breathing (SDB), chronic obstructive pulmonary disease (COPD), neuromuscular disease and other diseases. SDB includes obstructive sleep apnea (OSA) and other respiratory disorders that occur during sleep. Its cloud-based software digital health applications, along with its devices, are designed to provide connected care to improve patient outcomes. The Company's portfolio of products includes devices, diagnostic products, mask systems, headgear and other accessories, dental devices, portable oxygen concentrators (POCs) and cloud-based software informatics solutions. The Company produces Continuous Positive Airway Pressure (CPAP), Variable Positive Airway Pressure (VPAP) and AutoSet systems for the titration and treatment of SDB.
Home Page: www.resmed.com
RMD Technical Analysis
Allianz Funds
,
Phone:
858 836 5000
Officers
| Name | Title |
|---|---|
| Dr. Peter C. Farrell A.M., AM, B.E., BE (Hons), Ph.D., ScD | Founder & Non-Exec. Chairman |
| Mr. Michael J. Farrell BE, MBA, SM | CEO & Director |
| Mr. Robert A. Douglas | Pres & COO |
| Mr. Brett A. Sandercock | Chief Financial Officer |
| Mr. David B. Pendarvis | Chief Admin. Officer, Global Gen. Counsel & Corp. Sec. |
| Mr. Kaushik Ghoshal | Pres of SaaS Bus. |
| Ms. Urvashi Tyagi | Chief Technology Officer |
| Ms. Constance C. Bienfait | Director of Investor Relations |
| Ms. Amy Wakeham | VP of Investor Relations & Corp. Communications |
| Ms. Vered Keisar | Chief People Officer |
Exchange: AU
Country: AU
Currency: Australian Dollar (A$)
| Forward PE: | 35.461 |
|---|---|
| Trailing PE: | 39.47 |
| Price-to-Book MRQ: | 9.4564 |
| Price-to-Sales TTM: | 12.8402 |
| IPO Date: | |
| Fiscal Year End: | June |
| Full Time Employees: | 8160 |